Don't want ads? Subscribe or login now.

AstraZeneca Unit Ducks Patent Fraud, Not Sham Suit Claims

By Bryan Koenig · December 19, 2025, 6:48 PM EST

A Massachusetts federal judge spared AstraZeneca unit Alexion on Friday from half of a nonprofit insurer's proposed class action, finding the plaintiff too far removed from anticompetitive patent fraud that allegedly...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

EmblemHealth, Inc. v. Alexion Pharmaceuticals, Inc. et al

Case Number

1:25-cv-10985

Court

Massachusetts

Nature of Suit

Anti-Trust

Date Filed

April 16, 2025

Recent Articles By Bryan

December 17, 2025
Eating Disorder Pros Get 'One Final Attempt' Against Group
December 11, 2025
DOJ-UnitedHealth Deal Requiring Home Health Sale OK'd
December 04, 2025
Credit Bureaus Can't Duck Suit Over Excluded Medical Debt
December 03, 2025
AGs Say Sun, Taro Settlement Mustn't Touch State Claims
November 19, 2025
GTCR Wants FTC's In-House Merge Case Withdrawn Too
November 13, 2025
FTC Fails To Block Doctors' Testimony In $945M Merger Case
November 10, 2025
FTC Risks Help Push Metsera Back To Pfizer
November 07, 2025
Spurned Pfizer Turns To Antitrust Law To Reclaim Biotech
November 05, 2025
FTC Wants 'Tainted' Drs. Testimony Barred From Merger Case
October 30, 2025
Med Robot Co. Tells 9th Circ. Not To Revive 'Disfavored' Suit